BTIG keeps Buy ratings on Cullinan Therapeutics and OrthoPediatrics
BTIG reaffirmed Buy ratings on Cullinan Therapeutics and OrthoPediatrics, with price targets of $41 and $30. Source: TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
BTIG kept its Buy rating on Cullinan Therapeutics and set a price target of $41. According to the note, the shares closed at $14.84 on October 27, so the target implies a gain of 176.3%. Analysts highlighted the company's pipeline of bispecific T cell engagers, including CLN-978 and CLN-049, and the start of a Phase 1b/2a trial of velinotamig in autoimmune cytopenias.
BTIG also maintained its Buy rating on OrthoPediatrics with a $30 target. The company reported third-quarter 2026 revenue of about $72.7 million, up 18.6% year over year and ahead of both BTIG's estimates and consensus. It raised its full-year 2026 revenue guidance to $270–273 million. The target implies a 25.9% gain from the October 27 close of $23.82.
why it matters
Rating reviews of this kind appear regularly and rarely move the broader market. Investors typically focus more on reported results and updated company guidance than on a broker's price target. The information comes from TradingView, citing Benzinga data.
tags
instruments
sources
- BTIG maintains Buy rating on Cullinan Therapeutics, $41 price target — TradingView, 28 October 2026 at 09:54 UTC
- BTIG maintains Buy rating on OrthoPediatrics, $30 price target — TradingView, 28 October 2026 at 10:03 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗